PARD3

Across TCGA pan-cancer cohorts, PARD3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PARD3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PARD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PARD3 is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where PARD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PARD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.334	<.001	11	view →
CCRCC	Male	All	−0.210	<.001	10	view →
LUAD	All	III,IV	−0.346	<.001	9	view →
COAD	Male	All	−0.141	<.001	7	view →
LSCC	Male	II,III,IV	+0.190	.004	5	view →
PDAC	Female	II,III,IV	−0.395	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PARD3–HNSC

Open the HNSC breakdown →